Clinical Trials Logo

Clinical Trial Summary

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.


Clinical Trial Description

This study will consist of two treatment arms (Groups A and B). Participants will be randomised in a 1:1 ratio to one of the two treatment groups: - Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously. - Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05450692
Study type Interventional
Source AstraZeneca
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 15, 2022
Completion date August 22, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05621525 - Phase I Study of the BBP-398 in Patients With Advance Solid Tumors Phase 1
Completed NCT00716534 - Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT05388669 - A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Phase 3
Completed NCT02855125 - A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Phase 2